Zafgen announces positive full results in phase 2 proof-of-concept trial of ZGN-1061
Zafgen announced positive full results from the Company’s Phase 2 clinical trial of ZGN-1061, designed to demonstrate proof-of-concept efficacy and safety in patients with type 2 diabetes and establish a minimally effective dose. The trial met all of its primary endpoints at the 0.9 mg dose. June 23, 2018